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Shwachman–Diamond syndrome (SDS) is caused by mutations in the SBDS gene, most of which are the result of gene conversion events
involving its highly homologous pseudogene SBDSP. Here we describe the molecular characterization of the first documented gross deletion in
the SBDS gene, in a 4-year-old Portuguese girl with SDS. The clinical diagnosis was based on the presence of hematological symptoms (severe
anemia and cyclic neutropenia), pancreatic exocrine insufficiency and skeletal abnormalities. Routine molecular screening revealed heterozygosity
for the common splicing mutation c.258+2T>C, and a further step-wise approach led to the detection of a large deletion encompassing exon 3, the
endpoints of which were subsequently delineated at the gDNA level. This novel mutation (c.258+374_459+250del), predictably giving rise to an
internally deleted polypeptide (p.Ile87_Gln153del), appears to have arisen from an excision event mediated by AluSx elements which are present
in introns 2 and 3.
Our case illustrates the importance of including gross deletion screening in the SDS diagnostic setting, especially in cases where only one
deleterious mutation is detected by routine screening methods. In particular, deletional rearrangements involving exon 3 should be considered,
since Alu sequences are known to be an important cause of recurrent mutations.
© 2007 Elsevier Inc. All rights reserved.Keywords: Shwachman–Diamond syndrome; SBDS gene; SDS; Anemia; Neutropenia; Pancreatic insufficiency; Gross deletionIntroduction
Shwachman–Diamond syndrome (SDS; MIM #260400) is a
rare autosomal recessive disorder first described in 1964 [1]. The
association of bone marrow and exocrine pancreatic dysfunc-
tions characterizes this disease, which usually manifests
clinically in infancy or early childhood. Other systemic findings
(skeletal, liver and psychomotor) or problems secondary to bone
marrow dysfunction may also be present [1–4]. Intermittent or
persistent neutropenia, present in approximately 40% of the
patients, is the most common hematological finding, but anemia
and thrombocytopeniamay also be found [1–4]. Diagnosis is not
always obvious since mitochondrial respiratory chain (MRC)⁎ Corresponding author. Fax: +351 22 6070399.
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doi:10.1016/j.bcmd.2007.02.002disorders, particularly Pearson syndrome, share most of its
clinical manifestations.
The SDS locus was mapped to chromosome 7q11 where
disease-associated mutations were later reported in the Shwach-
man–Bodian–Diamond syndrome gene (SBDS; MIM #607444)
[5–7]. This gene comprises five exons spanning 7.9 kb, with a
1.6 kb transcript that translates into a protein of 250 amino acids
[6,7]. The SBDS protein is a member of a highly conserved
family with orthologs in several species. Although its function
remains to be elucidated, studies revealing ubiquitous expres-
sion with accumulation in the nucleolus in a cell-cycle-
dependent manner, as well as structural and co-expression
studies in the yeast orthologs, provide strong evidence for its
role in ribosome biogenesis [7–9].
The majority of mutations described in the SBDS gene are
said to represent gene conversion events due to recombination
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[7,10–13]. Many have been found to occur within a 240 bp
region around exon 2, which harbors the most frequent
mutations c.183_184TA>CT and c.258+2T>C. These are
often seen to be associated with the polymorphic variants
c.141C>T and/or c.201A>G, presumably as a result of the size
of the DNA fragments involved in the rearrangements
[7,9,10,12,13]. However, mutations may occur throughout the
gene, as evidenced by the 22 variants documented to date. Of
these, 50% are missense mutations and the remainder includes
splicing mutations (18%), small deletions (14%), del/ins
conversions (9%), small duplications (5%) and nonsense
mutations (5%) [7,9,10,12–15]. No gross deletions have been
reported in the SBDS gene.
We describe the molecular characterization of a Portuguese
patient with SDS, who was found to be compound heterozygous
for the known mutation c.258+2T>C and the hitherto
undocumented in-frame deletion of exon 3 (c.258+374_459
+250del). This deletion appears to have beenmediated by AluSx
repetitive sequences in the flanking introns.
Patient, materials and methods
Case report
This girl was the second child of a Caucasian non-
consanguineous couple, with irrelevant family history. Her
perinatal history was uneventful. She was admitted for the first
time at 3 months of age with failure to thrive, severe anemia
(hemoglobin: 5.6 g/dl), extensive eczema and liver enlargement
with hepatitis. She had multiple admissions in the first year of
life, for blood cell transfusions or serious clinical infections, due
to cyclic neutropenia. Investigation revealed bone marrow
dysfunction and persistent hepatitis.
Pearson syndrome was suspected and at 6 months of age she
was subjected to a muscle biopsy (no histological abnormal-
ities) and a liver biopsy (reactive chronic hepatitis and
hemosiderosis). MRC evaluation showed a decrease in complex
IV (25% of normal control average, in relation to citrate
synthase) in the muscle, and in complexes II (10%), II/IIIFig. 1. Skeletal abnormalities. Metaphyseal dysplasia is evident on the radiographs
irregularity of metaphyses of the long bones and the narrowing of the sacroiliac not(20%), IV (9%) and V (16%) in the liver. The mitochondrial
DNA study showed no common mutations. At 14 months of age
pancreatic insufficiency was evidenced (fecal elastase: 36 μg/g;
N>200 μg/g) and pancreatic enzyme supplementation was
introduced. At 17 months of age treatment with prednisone
(1 mg/kg/day) was started and maintained for 1 year. A second
liver biopsy, after 5 months on prednisone, evidenced mild
chronic hepatitis and normal activity of MRC enzymatic
complexes. SDS was then considered and a skeletal survey
revealed metaphyseal chondrodysplasia (Fig. 1). She is
presently 5 years old. Sustained recovery from anemia and
neutropenia occurred, but mild hepatitis, recurrent eczema and
short stature remains. Psychomotor development is normal.
Informed written consent was obtained from the parents for all
molecular studies.
gDNA analysis
Genomic DNA (gDNA) of the patient and her parents was
isolated from blood samples using standard methods. Direct
sequencing of all coding regions of the SBDS gene, including
exon–intron boundaries, was performed by cycle-sequencing
using polymerase chain reaction (PCR) primers as described
previously [10,16]. For analysis of intron 2, the following primers
were designed: g.SBDSI2F: 5′CCA CTC AGT GTT TGTAAA
TGT TTC TA and g.SBDSI2R: 5′TGT ATG GTC TCT TTG
TTT CAG GAT. Amplification of a 1870-bp fragment cor-
responding to exon 3 plus a large portion of its surrounding
intronic sequenceswas performed using the primers g.SBDS3bF:
5′TGC CCC ATT TATAGA ATG TGG TA and g.SBDS3bR: 5′
AAA GCA ACC CAA TGT CTA TCA AC. All PCR reaction
mixtures contained 25 μl PCR Master Mix (Promega, Madison,
USA), 22 μl water, 1 μl of each primer (each at 25 pmol/μl) and
1 μl gDNA (250 ng/μl). Amplification cycles consisted of an
initial denaturation step of 95 °C for 10 min, followed by 35
cycles of 95 °C for 1 min, 55 °C for 1 min and 72 °C for 2 min,
and with a final extension at 72 °C for 10 min.
A 3662-bp fragment, ranging from the beginning of exon 2 to
the end of exon 4, was amplified with primers SBDSEX2F [16]
and sds4R [10], using the Expand Long Template PCR Systemof the knees and hips of the proband at 3 years of age. Note the widening and
ch.
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according to the manufacturer's instructions. Thermal cycling
consisted of an initial denaturation step of 95 °C for 10 min,
followed by 35 cycles of 95 °C for 1 min, 55 °C for 1 min and
72 °C for 5 min, and a final extension at 72 °C for 30 min. All
amplification reactions were carried out in a GeneAmp PCR
System 9600 thermal cycler (Applied Biosystems, Foster City,
CA, USA).
For the sequencing reactions the amplicons were isolated by
electrophoresis on a 2% agarose gel and then purified using spin-
X® (Corning Incorporated, NY, USA). The nucleotide sequence
was determined using the respective forward and reverse
primers, in independent sequencing reactions, with the Dye
Terminator Cycle Sequencing Kit v1.1 (Perkin Elmer, Boston,
MA, USA). The products were resolved on anABI Prism 3130xl
Genetic Analyser (Applied Biosystems, Foster City, CA, USA).
cDNA analysis
Total RNAwas extracted from peripheral blood of the patient
and a control using TRIzol isolation reagent (Invitrogen, CA,
USA). Reverse transcription PCR (RT-PCR) was performed
with Superscript One-step RT-PCR and Platinum Taq polymer-
ase (Invitrogen, CA, USA) using the following 3 sets of primers:
c.SBDS1F: 5′CTG AAG CTA GTG AGT CGC GG and c.
SBDS1R: 5′TCAATAAGGATC ACG GTG TATGG (exons 1
to 3); c.SBDS2F: 5′GGA ACA GAT GAC CAA ACT GAA
ATC and c.SBDS2R: 5′CCG GGT CAA TCA GAC ATA CG
(exons 2 to 5); c.SBDS3F: 5′AAG AAA AGC TCA AGC CAC
TGA TC and c.SBDS3R: 5′CAG AGT AGC AAA ATG CCA
CTC TG (exons 4 to 5). Fragment isolation and sequencing were
carried out as described above.
Bioinformatic tools
Reference sequences used were GenBank NM_016038.2 for
cDNA and AC079920 for gDNA of the SBDS gene, as well as
NR_001588 for SBDSP. Mutation nomenclature was according
to the recommendations of the Human Genome Variation
Society (2005) (http://www.hgvs.org/mutnomen), using the
numbering convention which assigns “1” to the A of the
initiator ATG codon.
All of the new primers were designed so as to be SBDS-
specific. To that end, reference sequences retrieved from the
GenBank database were aligned using the ClustalX algorithm
[17], and primers were chosen with the aid of Primer Express
V2.0 software (Applied Biosystems, Foster City, CA, USA).
The possible involvement of cryptic splice sites was
evaluated by scanning the variant sequence with GENSCAN
software [18], that is designed to identify exon/intron structures
(http://genes.mit.edu/GENSCAN.html). In order to detect
homologous regions between introns 2 and 3, these were
compared using BLAST 2 Sequences [19] (http://www.ncbi.
nlm.nih.gov/blast/bl2seq/wblast2.cgi). The identification of
repetitive sequences was aided by the CENSOR on-line tool
[20], which screens queries against a reference collection of
repeats (http://www.girinst.org/censor/index.php).Results
Sequencing of the five exons of the SBDS gene from the
patient revealed only the presence of the knownmutation c.258+
2T>C7 (p.Cys84SerfsX3) and the c.201A>G polymorphism,
both in heterozygosity. Themother was found to carry the c.258+
2T>C mutation, whereas the father was heterozygous for three
previously described polymorphisms, namely c.129–
162TTGGGGGTAAGAAAdelinsGGGGGCGGGGG and
c.129–71G>A in intron 1, and c.201A>G in exon 2 [7,10].
The detection of a causal mutation associated with SDS and the
compatible clinical picture prompted the study of the mRNA of
the patient. cDNA analysis of the fragment encompassing
exons 2 to 5 revealed the presence of two bands, one apparently
normal sized and the other smaller than expected and that was
not detected in the control sample (Fig. 2A). Sequencing of the
patient's amplicons showed that those in the first band had an
8-bp deletion, known to be the expected product of the c.258+
2T>C mutation, whereas those in the smaller band were
missing the entire exon 3. The absence of exon 3 in the
transcript could be explained either by abnormal splicing due to
a mutation in one of the flanking introns, or by a gross genomic
deletion.
Investigation at the gDNA level ruled out aberrant splicing,
since only the allele carrying the c.258+2T>C mutation was
detected, upon intron analysis. Long-range gDNA PCR
encompassing exons 2 to 4 revealed an additional band that
was smaller than expected (normal fragment 3662 bp; variant
fragment ~2790 bp), which was also present in the patient's
father (Fig. 2B). Nested PCR and sequencing enabled the
characterization of the genomic breakpoints, disclosing a
deletion of 872 bp, which included the entire exon 3 and part
of the flanking intronic sequences. This alteration, character-
ized as c.258+374_459+250del, represents a new in-frame
deletion that translates into a protein missing an internal 67
amino acids (p.Ile87_Gln153del), and hence most of its central
domain.
In the context of genomic breakpoint analysis, large stretches
of homologous sequences were identified in introns 2 and 3.
Further investigation led to the conclusion that these were both
AluSx repeats, with the deletion breakpoints embedded therein
(Fig. 2C).
Discussion
SDS is a rare inherited multisystemic disorder characterized
by pancreatic insufficiency, bone marrow dysfunction and
skeletal changes. It may however involve other organs making
diagnosis difficult. SDS exceptionally presents with severe
anemia, as in this child [21], and on the other hand, MRC
disorders are far more frequent than SDS [22,23]. Pearson
syndrome was thus initially considered in this child, since the
non-specific gastrointestinal, hepatic and hematological symp-
toms are commonly found in MRC disorders, to variable
extents [24]. Diagnosis of MRC disorders is difficult and in
children it is still frequently based on functional studies. The
absence of a pathogenic mitochondrial or nuclear DNA
Fig. 2. Molecular characterization of the novel deletion. (A) cDNA analysis of amplicons representing exons 2 to 5. The patient presented two bands; one of almost
normal size, but with an 8-bp deletion associated with the c.258+2T>C mutation, and the other missing the whole of exon 3. (B) gDNA analysis of amplicons
representing exons 2 to 4. Long-range PCR revealed heterozygosity for the c.258+374_459+250del mutation, in the patient and in her father. (C) Alignment of AluSx
repeats in introns 2 and 3. The sequence deleted in the new mutation is shown in red. The box highlights a 21-bp tract of perfect homology which marks the deletion
breakpoints. MW—molecular weight marker; C—control; P—patient; M—mother; F—father.
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doubt remains as to the primary versus secondary nature of the
MRC dysfunction. In this patient, MRC deficiency would be
secondary, as favored by the observed reversal of liver
mitochondrial dysfunction after prednisone administration.
Besides the absence of the common mitochondrial DNA
deletion, the typical skeletal dysplasia finally led to the clinical
diagnosis of SDS.
In the molecular analysis of the SBDS gene, the presence of a
hotspot region in and around exon 2 has facilitated diagnosis,
and direct sequencing of this region has enabled the detection of
at least one mutated allele in about 90% of SDS patients ([5],
personal data). In the present case, the relatively frequent intron2 mutation c.258+2T>C was detected in heterozygosity, and
gDNA sequencing of all other exons and exon–intron bound-
aries failed to reveal further alterations.
The c.258+2T>C mutation is predicted to disrupt the donor
splice site consensus dinucleotide sequence of intron 2, with
subsequent use of an upstream cryptic donor splice site at
position c.251_252GT. The resulting 8-bp deletion at the end of
exon 2 in the respective transcript was described by Boocock et
al. [7] and was also seen to be the only product of this mutation
in the present case.
Extended cDNA analysis in our patient led to the identifica-
tion of a second aberrant transcript, seen to be lacking exon 3.
Sequential analysis at the gDNA level enabled the detection of a
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protein level, this in-frame exonic deletion is predicted to result
in the loss of 67 amino acids (p.I87_Q153del), which comprises
approximately 30% of the SBDS protein. In this region around
21% (14/67) of the residues are conserved or semiconserved,
when comparing the representative orthologs across a diversity
of species [8]. Recently, structural analysis of the SBDS
homologue from Archaeoglobus fulgidus (AF0491) revealed a
three-domain protein, where the central domain (residues 87–
160) was predicted to adopt a common fold — the winged
helix–turn–helix (wHTH) [8]. Such HTH domains are widely
used in DNA-binding and RNA-binding proteins of lower
eukaryotes, but may also, to some extent, be involved in
protein–protein interactions [8]. In the context of the human
SBDS protein, this domain corresponds to residues 98–169, a
region which is almost completely abolished by the in-frame
deletion described in the present study (residues 87–153). One
may thus speculate that the resulting mutant SBDS protein will
reflect the consequence of incorrect polypeptidic folding and
concomitant loss of function.
Unlike most mutations described to date, which are attributed
to conversion events resulting from the recombination between
SBDS and SBDSP [7–13], in the present case the deletion is
likely to have arisen from the mispairing of homologous
sequences and unequal crossing over between introns 2 and 3 of
the SBDS gene. When comparing the nucleotide sequence of
these introns, we found stretches of 263 bp in intron 2 and 257 bp
in intron 3 exhibiting approximately 80% homology. Further in
silico analysis identified these as Alu sequences with AluSx-
subfamily consensus.
The breakpoints of the deletion were found to coincide with
the AluSx elements, and more specifically, within a 21-bp
tract of perfectly homologous sequence near their 5′ ends (Fig.
2C). The fact that one copy of these tracts was deleted in its
entirety, in the junction sequence, provides strong evidence for
Alu-mediated homologous recombination as the mechanism
involved.
Since Alu sequences are known to account for recurrent
mutations [25,26], we believe it may be advantageous to screen
for deletional rearrangements involving exon 3 of the SBDS
gene. This may be particularly useful in clinically compatible
SDS cases where only one deleterious mutation is detected by
routine screening methods. In such cases, cDNA analysis and/or
Western blotting [9] would enable the detection of gross
rearrangements in general. This information should shed light
not only on the frequency (and recurrence rate) of the Alu-
mediated exon 3 deletion, but also provide evidence for or
against the monogenic nature of SDS.
An important implication in the failure to detect gross
heterozygous deletions is that the identification of a single
variant sequence may be erroneously interpreted as a homo-
zygous mutation, if masked by a coincident exonic deletion.
Moreover, the absence of the variant in one of the parents may be
mistaken as evidence of a de novo occurrence.
Accurate molecular diagnosis is important not only for
patient management, but also for genetic counseling of family
members. As such, it is now increasingly recognized thatscreening for exonic rearrangements should be implemented in
the routine diagnostic setting of many disorders, and our case
illustrates how this might be extensive to SDS.
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